Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00282425
Status:
TERMINATED
Last Update Posted:
2012-12-18
First Post:
2006-01-24
Brief Title:
Allogeneic Hematopoietic Stem Cell Transplantation NST for Patients With Systemic Sclerosis
Sponsor:
Richard Burt MD
Organization:
Northwestern University
Study Overview
Official Title:
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation NST for Patients With Systemic Sclerosis
Status:
TERMINATED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No subject enrolled since 2009
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Scleroderma is disease believed to be due to immune cells cells which normally protect the body but are now causing damage to the body There has not been any treatment that has been effective in treating this disease The likelihood of progression of the disease to severe disability and death is high This study is designed to examine whether treating patients with high dose Cyclophosphamide and Fludarabine drugs which reduce the function of your immune system and CAMPATH-1H a protein that kills the immune cells that are thought to be causing the disease followed by return of blood stem cells that have been previously collected from patients brother or sister will stop or reverse the disease The purpose of the Cyclophosphamide Fludarabine and CAMPATH-1H is to decrease immune system The purpose of the stem cell infusion is to restore blood production which will be severely impaired by the Cyclophosphamide Fludarabine and CAMPATH-1H and to produce a normal immune system that will no longer attack the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None